Why the study?
Does S-nitroso-cysteine (SNC) inhibit platelet aggregation and TxA2 synthesis in human blood platelets?
Does S-nitroso-cysteine (SNC) inhibit platelet aggregation and TxA2 synthesis in human blood platelets?
S-nitroso-cysteine inhibits human platelet aggregation through a cGMP-independent mechanism involving the inhibition of thromboxane A2 synthesis.
Answers are grounded in this paper and cite their sources.
SNC antiplatelet effects in animal models leave open translation to human antithrombotic therapy.
S-Nitroso-cysteine (SNC), a putative endothelium-derived relaxing factor, potently inhibited collagen- and arachidonic acid-induced platelet aggregation (IC50=100 nM) and thromboxane A2 (TxA2) synthesis of human blood platelets. ODQ, a selective inhibitor of the soluble guanylyl cyclase, inhibited SNC-induced formation of cGMP but did not reverse inhibition by SNC of collagen- and arachidonic acid-induced platelet aggregation. Combination of ODQ with SQ-29548, a specific platelet TxA2 receptor antagonist, did not modify the antiaggregatory action of SNC. Our study shows that SNC inhibits platelet aggregation by cGMP-independent mechanisms that may involve inhibition of TxA2 synthesis in human platelets.
No takes yet. Share an insight, caveat, or question.
Tsikas et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: